Crystalline phases of 5,6-dichloro-2-(isopropylamino)-(1 beta-l-ribofuranosyl)1h-benzimidazole
AssigneeTakeda Pharmaceutical Company Limited
InventorsGerard COQUEREL, Guillaume LEVILAIN, Marie-Noelle PETIT, Servane COSTE-LECONTE
Life of this patent
Estimating the term…
Abstract
The invention relates to novel crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-(.beta.-L-ribofuranosyl)-1H-benzimidazo-le (Maribavir), pharmaceutical compositions thereof and their use in medical therapy.
Claims2
A crystalline solvate of 5,6-dichloro-2-(isopropylamino)-1-(β-L-ribofuranosyl)-1H-benzimidazole, including a stoichiometric ratio of an organic solvent within a cavity of the crystal lattice, said solvent being selected from the group of:
- methanol, acetonitrile, ethyl acetate, diethylether, n-butylacetate, or 1-propanol, or mixtures thereof.
Crystalline Form VI of 5,6-dichloro-2-(isopropylamino)-1-(β-L-ribofuranosyl)-1H-benzimidazole, wherein said compound has unit cell parameters a=b=9.2825Å, c=41.602Å, and P41212 space group (recorded at 296 K).
Dependencies are inferred from the claim text.